Loading
The 2022 Barcelona Clinic Liver Cancer update refines the staging system that links liver cancer stage to treatment, incorporating immunotherapy as first-line systemic therapy, treatment stage migration and a more nuanced view of intermediate-stage disease.
Update of the BCLC staging and treatment algorithm for hepatocellular carcinoma covering very early, early, intermediate, advanced and terminal stages, with revised recommendations for resection, ablation, transplantation, transarterial therapies, and systemic therapy led by atezolizumab-bevacizumab and durvalumab-tremelimumab, plus the concepts of treatment stage migration and untreatable progression.
The BCLC stages used on this site's hepatocellular carcinoma pages and their default treatments follow this update.
Shares Intermediate hepatocellular carcinoma (BCLC B), Early hepatocellular carcinoma (BCLC 0 and A), Advanced hepatocellular carcinoma (BCLC C).
Shares Early hepatocellular carcinoma (BCLC 0 and A), Advanced hepatocellular carcinoma (BCLC C).
Shares Intermediate hepatocellular carcinoma (BCLC B), Advanced hepatocellular carcinoma (BCLC C).
Shares Intermediate hepatocellular carcinoma (BCLC B), Advanced hepatocellular carcinoma (BCLC C).
Shares Early hepatocellular carcinoma (BCLC 0 and A), Advanced hepatocellular carcinoma (BCLC C).
Shares Intermediate hepatocellular carcinoma (BCLC B), Early hepatocellular carcinoma (BCLC 0 and A).
Shares Intermediate hepatocellular carcinoma (BCLC B), Early hepatocellular carcinoma (BCLC 0 and A), Advanced hepatocellular carcinoma (BCLC C).
Shares Intermediate hepatocellular carcinoma (BCLC B), Advanced hepatocellular carcinoma (BCLC C).